BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30
• 31

• 

  Policy

  COVID-19 Becomes Legal Strategy for Convicted Insys Founder

  Insys founder John Kapoor is using the coronavirus pandemic as part of his legal defense to remain out of prison while he appeals his January racketeering conviction.

  March 23, 2020

   · 

  2 min read

   · 

  Alex Keown
• 

  Biotech Bay

  Gilead Suspends Access to Remdesivir Due to ‘Overwhelming Demand’ for the Experimental COVID-19 Treatment

  In order to continue to provide patients with access to the potential treatment, Gilead said it is in the process of transitioning from individual compassionate use requests to expanded access programs.

  March 23, 2020

   · 

  2 min read

   · 

  Alex Keown
• 

  Drug Development

  Malaria Drug and Antibiotic Combo May Work Against COVID-19, But Experts Warn Caution and Skepticism

  French researchers have published an article describing the potential use of a combination of hydroxychloroquine and the antibiotic azithromycin. The U.S. Food and Drug Administration is also evaluating the drugs but have not yet made recommendations.

  March 23, 2020

   · 

  4 min read

   · 

  Mark Terry
• 

  Business

  EU Pharma Strategy Targets Competition and the Environment

  Europe’s new pharmaceutical roadmap is designed to reinvigorate innovation in the pharmaceutical industry to make it competitive with the United States.

  March 23, 2020

   · 

  4 min read

   · 

  Gail Dutton
• 

  Policy

  Following November Adcom Vote, FDA Rejects Lilly and Boehringer’s Jardiance for Type 1 Diabetes

  The U.S. Food and Drug Administration issued a Completed Response Letter of Eli Lilly and Company and Boehringer Ingelheim’s Jardiance (empaglifozin) for type 1 diabetes.

  March 23, 2020

   · 

  2 min read

   · 

  Mark Terry
• 

  Drug Development

  Biopharma Industry News for March 23: Update on the Novel Coronavirus

  A summary of daily biopharma industry news. Please check out stories that are trending on March 23, 2020.

  March 23, 2020

   · 

  6 min read

   · 

  BioSpace Editorial Staff
• 

  Drug Development

  Biohaven Pharma Plans to Move Vazegepant into Phase III for Acute Migraine Treatment

  The company said the decision to advance the CGRP receptor antagonist into late-stage studies followed a successful end-of-phase meeting with the U.S. Food and Drug Administration.

  March 23, 2020

   · 

  2 min read

   · 

  Alex Keown
• 

  Policy

  World Health Organization Warns Against Untested Drugs for COVID-19

  “Using untested drugs without the right evidence could raise false hope and even do more harm than good and cause a shortage of essential drugs that are needed to treat other diseases,” said WHO Director-General Tedros Adhanom Ghebreyesus.

  March 23, 2020

   · 

  4 min read

   · 

  Mark Terry
• 

  Genetown

  Thermo Fisher Plans to Expand Manufacturing and Service Capabilities with $800 Million Investment

  For this year, 2020, it plans to invest more than $475 million in new capabilities and capacity.

  March 23, 2020

   · 

  2 min read

   · 

  Mark Terry
• 

  Drug Development

  Eli Lilly Among Companies Pausing Some Clinical Trials Due to COVID-19 Pandemic

  This morning, the Indianapolis-based company said it will delay most new study starts and pause enrollment in most ongoing studies in light of the COVID-19 pandemic.

  March 23, 2020

   · 

  3 min read

   · 

  Alex Keown